Central African Republic vs Niger: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Central African Republic
5.3%
in 2024
Niger
3.2%
in 2024
Central African Republic rank
1st
Niger rank
3rd
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Central African Republic
- Niger
How they compare
Central African Republic currently reports 5.3% against 3.2% in Niger, a difference of 2.1%.
That makes Central African Republic's figure about 1.7 times Niger's.
Across all 10 years both countries report, Central African Republic has been ahead every year.
Central African Republic ranks 1st and Niger ranks 3rd of 215 countries.
Central African Republic has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Central African Republic | Niger | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 10.0% | 2.6% | 7.4% | Central African Republic |
| 2020s | 7.0% | 3.4% | 3.5% | Central African Republic |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Central African Republic or Niger?
- Central African Republic, at 5.3% against 3.2% in Niger as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Central African Republic and Niger?
- 2.1%, with Central African Republic ahead.
- How many years of comparable data are there for Central African Republic and Niger?
- 10 years are reported by both, from 2015 to 2024.
- How do Central African Republic and Niger rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Central African Republic ranks 1st and Niger ranks 3rd of 215 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.